Bruker Corporation today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed.
Atinary Self-Driving Lab integrating Chemspeed robotics, a Fourier 80 FT-NMR, and Atinary's SDLabs agentic AI platform into a closed-loop workflow. The system automates liquid and solid reagent addition, catalyst addition, reaction execution, sampling with filtration, and inline NMR analysis, across many chemical reactions, including Suzuki and Buchwald-Hartwig. Scientists control the platform via SDLabs, leveraging AI agents to design experiments, navigate molecular spaces, execute runs, visualize and interpret results, and act on AI-guided recommendations for the next experiments, compounding the information each cycle in an R&D flywheel. These integrated systems can solve challenges that are intractable with traditional methods. Image Credit: Bruker Corporation
Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its agentic AI workflows. Atinary’s code-free SDLabs® platform applies AI agents and machine learning to design optimal experiments and deliver better and faster results with automated closed-loop Design-Make-Test-Analyze-Learn workflows. Running these integrated workflows generates high-quality, reproducible, and AI-ready datasets that are essential to train better models, increase success rates, and accelerate discovery.
Atinary and Chemspeed have established a joint demonstration laboratory at Chemspeed’s headquarters near Basel, Switzerland. Atinary’s Self-Driving Lab in Boston opened in early 2026 as a Scientific Data Factory to bring better molecules and products to market faster. The Atinary Lab includes Chemspeed robotics and Bruker benchtop NMR, as well as automation and measurement tools by other vendors, focusing on small-molecule synthesis and catalysis in pharmaceutical R&D and process development.
“Cross-coupling reactions have had a significant impact on the discovery and manufacturing of pharmaceuticals, as well as in other industries,” said Professor Stephen Buchwald, Camille Dreyfus Professor of Chemistry at MIT and Scientific Advisor to Atinary Technologies. “However, the full potential of this chemistry, particularly C-N coupling, remains untapped. Large parameter spaces, combining catalysts, ligands, bases, solvents, and temperature, are complex and difficult to navigate. Generating rigorous, reproducible, lab-validated datasets could lead to significant advances. I am excited to be a part of the Atinary team and to explore what is possible when their approaches are employed to tackle meaningful scientific challenges in their lab.”
"Atinary's mission is to augment humans with AI and robotics to accelerate scientific discovery exponentially and tackle key planetary challenges," said Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies. "Together with our team, ecosystem, and clients, we design and enable Self-Driving Labs as R&D flywheels, where every experiment makes the next one smarter, compounding the information from real-world lab data."
“Our strategic investment in Atinary advances Bruker’s goal to combine differentiated analytical technologies with lab automation, scientific software and AI-guided experimentation,” said Bernd Gleixner, President of the Chemspeed Division. “The Atinary SDLabs in Basel and Boston demonstrate closed-loop R&D workflows powered by agentic AI. We intend to build on this foundation by extending the collaboration to additional analytical solutions and customer applications.”